FDA rejects Daiichi Sankyo's application for pain medication

The FDA declared the application for CL-108, as it stands, not approved.
The FDA declared the application for CL-108, as it stands, not approved. | File photo
The U.S. Food and Drug Administration issued a complete response letter in response to Daiichi Sankyo's new drug application regarding CL-108, a drug used in treating and managing pain.
The FDA declared the application, as it stands, not approved and is providing guidance on information needed to resolve the issues.
Based in New Jersey, Daiichi Sankyo is a pharmaceutical manufacture working to address unmet health care needs.  

Want to get notified whenever we write about Daiichi Sankyo, Inc. ?
Next time we write about Daiichi Sankyo, Inc., we'll email you a link to the story. You may edit your settings or unsubscribe at any time.
Organizations in this story

Daiichi Sankyo, Inc. 2 Hilton Ct Parsippan, NJ 07054